Top Domperidone Brands You Can Trust

In the vast world of pharmaceuticals, selecting the right brand for medications like domperidone can significantly impact patient satisfaction and therapeutic outcomes. Domperidone is widely used to address gastrointestinal issues, and as such, several brands have emerged as trusted sources for this medication. It's crucial to consider factors such as efficacy, side effects, and patient reviews when choosing a brand. For those interested in a comprehensive guide to the best domperidone brands, discover the detailed list below.

Illustration of domperidone

Best brands of domperidone in 2025

Motilium

Motilium, developed by Janssen Pharmaceutica, is a leading brand for domperidone, a dopamine antagonist used to treat nausea, vomiting, and gastrointestinal issues like gastroparesis. Introduced in 1979, Motilium offers a modest bioavailability of 13-17% when taken orally and significantly increases prolactin levels, with a 13.7-fold rise observed in non-lactating women after a single 20 mg dose. While available over-the-counter in many countries, it is not approved for general use in the United States. Domperidone's low central nervous system penetration minimizes extrapyramidal side effects, ensuring safer usage. Over the years, the drug has evolved through various formulations, including the introduction of orally disintegrating tablets in 1999.

Domstal

Domstal, manufactured by Torrent Pharmaceuticals Ltd, is a leading brand for domperidone, widely used to treat nausea, vomiting, and motion sickness, as well as indigestion, heavy bloating, heartburn, and stomach fullness. It is available in 5mg and 10mg tablet forms and is known for its efficacy, providing relief within 6-8 hours of administration. India, where Torrent Pharmaceuticals is based, dominates the global domperidone market with a 92% market share in shipments. Domstal is prescribed by healthcare professionals and has a notable presence in the gastrointestinal therapy segment. The drug has been effective in increasing milk production in breastfeeding mothers when prescribed appropriately.

Vomistop

Vomistop, produced by Cipla Ltd, is a highly effective medication for treating nausea, vomiting, and indigestion, containing the active ingredient domperidone. It works by blocking dopamine receptors in the brain and upper intestine, increasing the motility of the upper gastrointestinal tract and reducing gastric emptying time. Users have reported significant improvement, with 46% rating the improvement as excellent and 78% using it primarily for vomiting. Common side effects are temporary and include headache, dry mouth, and stomach pain. The medication should be taken half an hour before meals and not for more than seven days without consulting a doctor. For more details, visit their Vomistop product page.

Domperon

Domperidone, particularly the brand produced by Wockhardt, is highly regarded for its efficacy in treating gastrointestinal disorders, such as nausea, vomiting, and gastric motility issues. The market for domperidone is expected to grow at a CAGR of 4.9% from 2024 to 2031, reaching a value of USD 1120.4 million by 2031, driven by increasing demand for treatments of gastroparesis and chronic nausea. Wockhardt's formulation is notable for its adherence to the recommended dose of 10 mg orally up to three times daily, or 30 mg as a suppository twice a day, ensuring patient safety and minimizing cardiac risks. The drug's widespread use is also supported by its availability in various forms, including oral tablets, oral suspension, and suppositories. Despite safety concerns, the overall benefit-risk balance of domperidone remains positive, especially when used at the lowest effective dose for the shortest possible duration.

Domperidone

The Domperidone market, with Teva Pharmaceuticals as one of its key players, is experiencing significant growth driven by the increasing prevalence of gastrointestinal diseases and the rising geriatric population. In 2023, the Domperidone market was valued at USD 745.8 million and is projected to reach USD 1120.4 million by 2031, growing at a CAGR of 4.9% from 2024 to 2031. Teva Pharmaceuticals, along with other major companies, contributes to this growth through its extensive product range, including oral tablets, oral suspension, and intravenous solutions. The market expansion is also fueled by improvements in healthcare infrastructure, especially in the Asia-Pacific region, and growing awareness of digestive health. Teva's strong presence in the global market is further bolstered by its innovative products and strategic collaborations.

Perinorm

Perinorm, a brand of domperidone produced by Sun Pharma, is recognized for its efficacy in treating gastrointestinal disorders and its off-label use in stimulating lactation. Domperidone, as found in Perinorm, increases prolactin levels, leading to a significant increase in breast milk volume, with studies showing a mean increase of 96.3% in milk volume. It is available in 10 mg tablets, with the recommended daily dose not exceeding 30 mg to minimize side effects such as psychiatric withdrawal events upon discontinuation. Perinorm is widely used due to its peripheral dopamine antagonist properties, which minimize central nervous system adverse effects compared to other dopamine receptor antagonists like metoclopramide. As of 2021, approximately 1.7 million prescriptions for domperidone, including Perinorm, were filled in Canada across all indications. For more details about Perinorm, visit Sun Pharma's official website.

Dominate

Domperidone, particularly the brand Dominate by Alkem Laboratories, stands out as a leading producer in the market, known for its high efficacy in managing gastrointestinal disorders such as nausea, vomiting, and gastroparesis. With a global demand growing at a CAGR of approximately 5-7%, Dominate has captured a significant share, especially in regions like Asia-Pacific and North America. The brand's innovative formulations, including sustained release microspheres, enhance patient compliance and treatment outcomes. As of 2024, the domperidone market is poised for steady growth, driven by increasing healthcare investments and advancements in pharmaceutical technology. Dominate's commitment to quality and affordability aligns with the rising need for effective gastrointestinal treatments.

Dom DT

Dom DT by Mankind Pharma is a highly regarded brand for domperidone, known for its efficacy in treating gastrointestinal issues and boosting breastmilk supply. The drug has shown significant increases in milk production, with studies indicating a 45% increase in daily milk output in some cases. Domperidone's global market, which includes brands like Dom DT, is projected to grow at a 4.9% CAGR from 2024 to 2031, reaching a market size of USD 1120.4 million by 2031. The drug's popularity is driven by its ability to increase prolactin levels, thereby stimulating breastmilk production. With its widespread availability in countries like the UK, Europe, Canada, and New Zealand, Dom DT remains a trusted choice. For more details about Dom DT tablets, visit their website.

Dompan

Dompan, a brand by Panacea Biotec, is a prominent producer of domperidone, contributing significantly to the global market. The domperidone market, valued at USD 745.8 million in 2023, is expected to grow at a 4.9% CAGR from 2024 to 2031, reaching USD 1120.4 million by 2031. Dompan's products, including oral tablets, oral suspension, and intravenous solutions, are widely used to treat gastrointestinal disorders, nausea, and gastroparesis. The brand's effectiveness and patient compliance are enhanced by advancements in medication formulation and delivery techniques. As healthcare access improves globally, Dompan is poised to benefit from the increasing demand for efficient therapies. For more information, visit the Panacea Biotec website.

Dom

Domperidone, particularly from brands like Centaur Pharmaceuticals, is a widely used medication for treating gastrointestinal disorders, despite not being FDA-approved for human use in the U.S. The global domperidone market, which includes products from such manufacturers, was valued at USD 745.8 million in 2023 and is expected to grow at a 4.9% CAGR from 2024 to 2031, reaching USD 1120.4 million by 2031. Domperidone is extensively used to treat nausea, gastroparesis, and other gastrointestinal issues, driving its market expansion. However, its use for lactation has been associated with serious cardiac and neuropsychiatric adverse events. The drug's effectiveness in stimulating lactation remains unestablished. For more information, you can visit the FDA's official information about domperidone.